PEARLS , a large scale trial of antiretroviral therapy ( ART ) for HIV ( n = 1,571 , 9 countries , 4 continents ) , found that a once-daily protease inhibitor ( PI ) based regimen ( ATV+DDI+FTC ) , but not a once-daily non-nucleoside reverse transcriptase inhibitor/nucleoside reverse transcriptase inhibitor ( NNRTI/NRTI ) regimen ( EFV+FTC / TDF ) , had inferior efficacy compared to a standard of care twice-daily NNRTI/NRTI regimen ( EFV +3 TC/ZDV ) .